Does Rallies show 13F holders for MDXG?

Yes. Rallies tracks hedge fund and 13F ownership data for MDXG, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MDXG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MDXG. It does not provide personalized investment advice.

MDXG (MiMedx Group, Inc) Stock Analysis - Hedge Fund Holdings

MiMedx Group, Inc (MDXG) is a publicly traded Healthcare sector company. As of May 21, 2026, MDXG trades at $3.79 with a market cap of $534.72M and a P/E ratio of 11.35. MDXG moved +4.40% today. Year to date, MDXG is -40.13%; over the trailing twelve months it is -47.14%. Its 52-week range spans $3.03 to $10.14. Analyst consensus is strong buy with an average price target of $6.20. Rallies surfaces MDXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MDXG stock?

Hedge funds tracked by Rallies that own MDXG include Chilton Investment and Centerbook Partners. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MiMedx Group, Inc.

MDXG Key Metrics

Key financial metrics for MDXG
Metric	Value
Price	$3.79
Market Cap	$534.72M
P/E Ratio	11.35
EPS	$0.33
Dividend Yield	0.00%
52-Week High	$10.14
52-Week Low	$3.03
Volume	300
Avg Volume	0
Revenue (TTM)	$418.63M
Net Income	$48.58M
Gross Margin	82.56%

Top Hedge Funds Holding MDXG

Chilton Investment holds 18.01K shares of MDXG, changed +0.00% as of Dec 31, 2024.
Centerbook Partners holds 13.61K shares of MDXG, changed +0.00% as of Mar 31, 2026.

Latest MDXG News

MiMedx Launches G4Derm Plus Nationwide, Secures Premier and Vizient GPO Agreements — May 8, 2026
MiMedx Cuts 2026 Sales Forecast to $260M–$290M After Q1 Sales Slide 33% — Apr 29, 2026
MiMedx Q1 Revenue Forecast at $70m and EPS Loss of $0.03; 2026 Outlook Cut — Apr 28, 2026
MiMedx to Cut $40M in Annual Costs, Takes $4M Q2 Charge — Apr 16, 2026
MIMEDX to Present G4Derm Plus Data at SAWC and DLS Conferences — Apr 2, 2026

Recent MDXG Insider Trades

Maersk-Moller Kimberly sold 58.30K (~$432.33K) on Nov 6, 2025.
Capper Joseph H bought 200.00K (~$1.27M) on May 2, 2025.
Maersk-Moller Kimberly sold 1.76K (~$14.14K) on Mar 17, 2025.

MDXG Analyst Consensus

5 analysts cover MDXG: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.20.

Common questions about MDXG

Who owns MDXG stock?: Hedge funds tracked by Rallies that own MDXG include Chilton Investment and Centerbook Partners. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for MiMedx Group, Inc.
Does Rallies show 13F holders for MDXG?: Yes. Rallies tracks hedge fund and 13F ownership data for MDXG, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MDXG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MDXG. It does not provide personalized investment advice.